Endocrine, Metabolic & Immune Disorders - Drug Targets(Formerly Current Dru

Implications of the Obesity Epidemic for Statin Therapy: Shifting Cholesterol Metabolism to a High Synthesis and Low Dietary Absorption State
pp. 153-166(14)
Authors: Hoenig, Michel R.; Kostner, Karam M.; Read, Stephen J.; Walker, Philip J.; Atherton, John J.

Remote Preconditioning- Endocrine Factors in Organ Protection Against Ischemic Injury
pp. 167-175(9)
Authors: Bolte, Craig S.; Liao, Siyun; Gross, Garrett J.; Schultz, Jo El J.

Therapeutic Use of Molecules that Mimic Pathogen Danger Signals
pp. 177-186(10)
Author: Eyles, Jim E.

Tumor Necrosis Factor Alpha in Ulcerative Colitis and Diverticular Disease Associated Colitis
pp. 187-194(8)
Authors: Hassan, C.; Zullo, A.; De Francesco, V.; Campo, S. M.A.; Morini, S.; Panella, C.; Ierardi, E.

Vulnerable Plaque Versus Vulnerable Patient: Emerging Blood Biomarkers for Risk Stratification
pp. 195-201(7)
Authors: Paramo, J. A.; Rodriguez, J. A.; Orbe, J.

Tolerance in the Absence of Autoantigen
pp. 203-210(8)
Authors: Pascual, D. W.; Ochoa-Reparaz, J.; Rynda, A.; Yang, X.

Neuroinflammation and its Modulation by Flavonoids
pp. 211-224(14)
Authors: Vafeiadou, K.; Vauzour, D.; Spencer, J. P.E.

Trends in the Exploration of Therapeutic Targets for the Treatment of Endocrine, Metabolic and Immune Disorders
pp. 225-231(7)
Authors: Chen, X.; Zheng, C. J.; Han, L. Y.; Xie, B.; Chen, Y. Z.